Tue Feb 25 19:30:00 UTC 2025: **Trump’s Stance on Cannabis Rescheduling Remains Unclear Amidst Growing National Support**

**Washington, D.C. –** With federal cannabis rescheduling a hot-button issue in the 2024 election, the potential actions of a second Trump administration are under intense scrutiny. While cannabis reform gained significant traction under President Biden, the ambiguity surrounding a potential Trump approach leaves the industry and voters uncertain.

Currently, cannabis is classified as a Schedule I drug, alongside heroin and LSD, hindering research and access to basic banking services for businesses. Rescheduling to Schedule II or III would significantly alter the landscape, potentially facilitating research and providing federal banking access for dispensaries. However, it’s crucial to note that rescheduling would not equate to full legalization; challenges such as the IRS Code 280E tax burden would remain.

Trump’s past stance on cannabis has been inconsistent. While he expressed support for states’ rights on the issue, his Attorney General, Jeff Sessions, revoked the Cole Memo in 2018, creating uncertainty for the industry. Conversely, Trump signed the 2018 Farm Bill, legalizing hemp and CBD, a significant victory for cannabis advocates.

Analysts suggest that rescheduling could be a strategic move for Trump, appealing to both conservative and pro-cannabis voters. The potential for substantial tax revenue and strong public support for reform make federal cannabis policy a potentially defining issue in the upcoming election. Whether Trump will embrace or ignore this growing momentum remains to be seen.

Read More